A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2018
At a glance
- Drugs Timbetasin (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- Sponsors G-treeBNT; Lenus Therapeutics
- 11 Nov 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Nov 2019.
- 11 Jul 2018 New trial record